Save
Long-term efficacy and safety of teriflunomide: an analysis of pooled clinical trials
Author(s): ,
M.S. Freedman
Affiliations:
University of Ottawa and the Ottawa Hospital Research Institute, Ottawa, ON, Canada
,
L. Ramió-Torrentà
Affiliations:
Girona Neuroimmunology and Multiple Sclerosis Unit, Neurology Department, Dr. Josep Trueta University Hospital
,
M. Zaffaroni
Affiliations:
Multiple Sclerosis Study Center, Gallarate Hospital, ASST Valle Olona, Gallarate, Italy
,
J. De Seze
Affiliations:
Strasbourg University, Hôpital Civil, Strasbourg, France
,
S. Ahn
Affiliations:
Department of Neurology, Chung-Ang University College of Medicine, Seoul, Republic of Korea
,
R. Macdonell
Affiliations:
Department of Neurology, Austin Health, Heidelberg, VIC, Australia
,
A.E. Miller
Affiliations:
Icahn School of Medicine at Mount Sinai, New York, NY, United States
,
B. Kallmann
Affiliations:
Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Würzburg, Würzburg, Germany
,
D. Rog
Affiliations:
Greater Manchester Neurosciences Centre, Salford, United Kingdom
,
M. Benamor
Affiliations:
Sanofi, Chilly-Mazarin, France
,
P. Truffinet
Affiliations:
Sanofi, Chilly-Mazarin, France
,
J. Chavin
Affiliations:
Sanofi, Cambridge, MA, United States
,
E. Poole
Affiliations:
Sanofi, Cambridge, MA, United States
C. Lebrun-Frenay
Affiliations:
Hôpital Pasteur 2, Nice, France
ECTRIMS Online Library. Freedman M.
Oct 12, 2018; 229073
Mark S. Freedman
Mark S. Freedman
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Discussion Forum (0)
Rate & Comment (0)

Abstract: P1233

Type: Poster Sessions

Abstract Category: Therapy - Long-term treatment monitoring

Background: Teriflunomide is a once-daily oral immunomodulator approved for the treatment of relapsing forms of MS. The efficacy of teriflunomide has been demonstrated in Phase 2 (NCT01487096) and Phase 3 (TEMSO [NCT00134563; NCT00803049], TOWER [NCT00751881], TENERE [NCT00883337]) studies. Available evidence suggests that teriflunomide does not significantly impact protective immunity.
Objective: To report long-term (up to 12.8 years) efficacy and safety data from a pooled analysis of the Phase 2 and Phase 3 TEMSO, TOWER, and TENERE core and extension studies.
Methods: In the Phase 2 study, TEMSO, and TOWER, patients were randomized 1:1:1 to receive placebo or teriflunomide 7 mg or 14 mg. In TENERE, patients were randomized 1:1:1 to receive subcutaneous interferon beta-1a 44 µg (IFN) or teriflunomide 7 mg or 14 mg. In the extensions, teriflunomide-treated patients either continued on their original dose of teriflunomide (Phase 2, TEMSO) or received teriflunomide 14 mg regardless of original dose (TOWER, TENERE), while placebo- or IFN-treated patients were reassigned 1:1 to teriflunomide 7 mg or 14 mg (Phase 2, TEMSO) or received teriflunomide 14 mg (TOWER, TENERE). Efficacy and safety data were pooled from the Phase 2, TEMSO, TOWER, and TENERE core and extension studies (teriflunomide and placebo groups only). Annualised relapse rates (ARRs) and overall AE rates for patients treated with teriflunomide 14 mg in the core studies are presented; extension data will be available for presentation.
Results: There were 812 and 896 patients in the pooled placebo and teriflunomide 14 mg intention-to-treat groups, respectively. The cumulative treatment exposure for teriflunomide 14 mg was 1357 patient years. Adjusted ARRs (95% CI) were significantly lower among patients treated with teriflunomide 14 mg (0.38 [0.33, 0.43]) compared with placebo (0.59 [0.52, 0.67]), representing a relative reduction of 35% (P< 0.0001). In the placebo and teriflunomide 14 mg groups, the percentage of patients with AEs was 86.4% and 89.7%, respectively; the percentage of patients with serious AEs was 12.4% and 12.8%, respectively; and the percentage of patients who discontinued treatment due to AEs was 6.9% and 13.1%, respectively. Detailed data on AEs will be presented.
Conclusions: ARRs were significantly lower among patients treated with teriflunomide 14 mg vs placebo. No new safety signals were reported.
Disclosure: MF: Research/educational grant support from Bayer and Genzyme; honoraria/consulting fees from Bayer, Biogen, EMD Canada, Novartis, Sanofi, and Teva; member of company advisory boards/board of directors/other similar group for Bayer, Biogen, Chugai, Merck Serono, Novartis, Opexa Therapeutics, Sanofi, and Teva. LRT: Received honoraria for serving on advisory boards and as a speaker, and educational support from Biogen, Sanofi, Genzyme, Merck, Novartis, Teva, Mylan and Almirall. MZ: Received honoraria for speaking or for serving in advisory boards and received funding for traveling from Almirall, Biogen, Genzyme, Merck Serono, and Novartis. JDS: Provided consulting services and taken part in advisory boards for Sanofi. SA: Nothing disclosed. RM: Consulting/speaker fees from Bayer, Biogen, Genzyme, Merck, Sanofi, Serono, Novartis, Roche. AM: Consulting fees from Accordant Health Services, Acorda Therapeutics, Alkermes, Biogen, EMD Serono, Genentech, Roche, Genzyme, GSK, Mallinckrodt Pharmaceuticals [Questcor], Novartis, Roche, and Teva; contracted research for Biogen, Genentech, Novartis, Questcor, Roche, and Sanofi. BK: Received honoraria for serving on advisory boards and as a speaker from Biogen, Sanofi, Genzyme, Merck Serono, Novartis, and Teva. DR: Consulting fees from Bayer, Biogen, MedDay, Merck Serono, Novartis, Roche, Sanofi, and Teva; research support from Biogen, Genzyme, GW Pharma, Merck Serono, Mitsubishi, Novartis, and Teva. MB: Employee of Sanofi with ownership interest. PT: Employee of Sanofi, with ownership interest. JC: Employee of Sanofi with ownership interest. EP: Employee of Sanofi with ownership interest. CLF: Consulting fees, honoraria, or scientific committee support from Biogen, Genzyme, MedDay, Merck Serono, Novartis, Roche, and Teva.
Study supported by Sanofi

Code of conduct/disclaimer available in General Terms & Conditions
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings